1. Scrip
  2. >>Business

Vertex Joins Regulus In Kidney Disease Therapy Hunt

 
• By Andrew McConaghie

The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.

Vertex R&D
Vertex's research facility in San Diego. • Source: Shutterstock

Competition to develop new treatments for autosomal dominant polycystic kidney disease (ADPKD) is ramping up, with Vertex ready to begin trials of a potential disease modifying treatment – but rival Regulus Therapeutics is several steps ahead.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.